The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunodeficiency virus type 1 (HIV-1)-infected patients, whereas the NA response against autologous HIV-1 virus isolates is highly type-specific, motivated us to study the type- and group-specific NA responses generated upon presentation of escape virus, and the viral epitopes involved in the escape. Patients with demonstrable escape virus all developed group-specific NA, which were detectable after a delay and disappeared prior to disease development. The sera tested inhibited the binding of recombinant soluble gp120IIIB to cell-associated CD4, but group-specific virus neutralization required binding of NA to HIV-1 prior to viral attachment to target cells. Consecutive escape virus isolates were tested for sensitivity to neutralization by heterologous sera. Only minor differences were demonstrated, suggesting that the majority of the change in neutralization sensitivity is driven by the selective pressure of type-specific NA. Furthermore, no differences were observed in sensitivity to neutralization by anti-carbohydrate neutralizing monoclonal antibodies or the lectin concanavalin A, indicating a conserved nature of certain carbohydrate neutralization epitopes during escape. Finally the V3 sequence of three sets of consecutive virus isolates were analysed revealing amino acid mutations in V3 sequences of all escape virus isolates. The biological significance of these variations was confirmed further by the demonstration of changes in sensitivity to neutralization by anti-V3 monoclonal antibodies. These results strongly suggest a participation of the NA response against the V3 loop in the immunoselection of escape virus.
AlbertJ.,
AbrahamssonB.,
NagyK.,
AureliusE.,
GainesH.,
NyströmG.,
FenyöE. M.1990; Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107–112
ArendrupM.,
NielsenC. M.,
HansenJ.-E. S.,
MathiesenL.,
LindhardtB., Ø.,Scheibel,E.& NielsenJ. O.1992b; Neutralizing antibodies against two HIV-1 strains in consecutively collected serum samples: cross neutralization and association to HIV-1 related disease. Scandinavian Journal of Infectious Diseases 24:21–28
BenjouadA.,
GluckmanJ.-C.,
RochatH.,
MontagnierL.,
BahraouiE.1992; Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gpl60. Journal of Virology 66:2473–2483
BerkowerI.,
MurphyD.,
SmithC. C.,
SmithG. E.1991; A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gpl20. Journal of Virology 65:5983–5990
BolmstedtA.,
HemmingA.,
FlodbyP.,
BerntssonP.,
TravisB.,
LinnJ. P. C.,
LedbetterJ.,
TsuT.,
WigzellH.,
HuS.-L.,
OlofssonS.1991; Effects of mutations in glycosylation sites and disulphide bonds on the processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins. Journal of General Virology 72:1269–1277
GaubJ.,
PedersenC.,
PoulsenA. G.,
MathiesenL. R.,
UlrichK.,
LindhardtB. O.,
FaberV.,
GerstoftJ.,
HofmannB.,
LernestedtJ. O.,
NielsenC. M.,
NielsenJ. O.,
PlatzP.1987; The effect of Foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1:27–33
HansenJ.-E. S.,
ClausenH.,
NielsenC.,
TeglbjærgL. S.,
HansenL. L.,
NielsenC. M.,
DabelsteenE.,
MathiesenL.,
HakomoriS.-I.,
NielsenJ. O.1990; Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gpl20 may be a target for virus neutralization. Journal of Virology 64:2833–2840
HansenJ.-E. S.,
NielsenC.,
VestergaardB. F.1991b; Inhibition of human immunodeficiency virus 1 (HIV-1) and herpes simplex virus 1 (HSV-1) infectivity with a broad range of lectins. Scandinavian Journal of Infectious Diseases 23:425–430
HaradaS.,
YamamotoN.1985; Quantitative analysis of AIDS-related virus-carrying cells by plaque-forming assay using an HTLV-I positive MT-4 cell line. Japanese Journal of Cancer Research 76:432–135
KangC.-Y.,
NaraP.,
ChamatS.,
CaralliV.,
RyskampT.,
HaigwoodN.,
NewmanR.,
KohlerH.1991; Evidence for non-V3-specific neutralizing antibodies that interfere with gpl20/CD4 binding in human immunodefiency virus 1-infected humans. Proceedings of the National Academy of Sciences, U.S.A. 88:6171–6175
LaRosaG. J.,
DavideJ. P.,
WeinholdK.,
WaterburyJ. A.,
ProfyA. T.,
LewisJ. A.,
LangloisA. J.,
DreesmanG. R.,
BoswellR. N.,
ShadduckP.,
HolleyL. H.,
KarplusM.,
BolognesiD. P.,
MatthewsT. J.,
EminiE. A.,
PutneyS.1990; Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932–935
LinsleyP. S.,
LedbetterJ. A.,
Kinney-ThomasE.,
HuS. L.1988; Effects of anti-gpl20 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. Journal of Virology 62:3695–3702
NielsenC.,
NielsenC. M.,
PetersenJ. L.,
GotzschP. C.,
PedersenC.,
ArendrupM.,
VestergaardB. F.1991; Isolation of HIV from cultures of purified CD4+ lymphocytes. Journal of Virological Methods 35:15–25
OhS.-K.,
CruikshankW. W.,
RainaJ.,
BlanchardG. C.,
AdlerW. H.,
WalkerJ.,
KornfeldH.1992; Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. Journal of Acquired Immune Deficiency Syndromes 5:251–256
PalkerT. J.,
ClarkM. E.,
LangloisA. J.,
MatthewsT. J.,
WeinholdK. J.,
RandallR. R.,
BolognesiD. P.,
HaynesB. F.1988; Type-specific neutralization of the human immunodeficiency virus with antibodies to env-coded synthetic peptides. Proceedings of the National Academy of Sciences, U.S.A. 85:1932–1936
ReitzM. S.,
WilsonC.,
NaugleC.,
GalloR. C.,
Robert-GuroffM.1988; Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57–63
Robert-GuroffM.,
ReitzM. S.,
RobeyW. G.,
GalloR. C.1986; In vitro generation of an HTLV-III variant by neutralizing antibody. Journal of Immunology 137:3306–3309
SchnittmanS. M.,
LaneH. C.,
RothJ.,
BurrowsA.,
FolksT. M.,
KehrlJ. H.,
KoenigS.,
BermanP.,
FauciA. S.1988; Characterization of gpl20 binding to CD4 and an assay that measures ability of sera to inhibit this binding. Journal of Immunology 141:4181–4186
SkinnerM. A.,
TingR.,
LangloisA. J.,
WinholdK. J.,
LyerlyH. K.,
JavaherianK.,
MatthewsT. J.1988; Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Research and Human Retroviruses 4:187–197
SönnerborgA.,
BergstromT.,
JohanssonB.,
HäkanssonC.,
JulanderI.,
NorkransG.,
SvennerholmB.,
StrannegärdÖ.1991; Demonstration of HIV-1 DNA in immunocompetent HIV-1 antibody positive, but not in seronegative, homosexual men. Immunology and Infectious Diseases 1:85–89
TremblayM.,
WainbergM. A.1990; Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. Journal of Infectious Diseases 162:735–737
WeissR. A.,
ClaphamP. R.,
Cheingsong-PopovR.,
DalgleishA. G.,
CarneC. A.,
WellerI. V. D.,
TedderR. S.1985; Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature, London 316:69–72
ZwartG.,
LangedijkH.,
HoekL.,
JongJ. J.,
WolfsT. F. W.,
RamautarsingC.,
BarkerM.,
RondeA.,
GoudsmitJ.1991; Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181:481–189